Lercanidipine in the treatment of hypertension

Annals of Pharmacotherapy

Volumn 41, Issue 3, 2007, Pages 465-474

  Beckey, Cherylyn ^a   Lundy, Amber ^b   Lutfi, Nahla ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcium channel blocker; Dihydropyridine; Hypertension; Lercanidipine

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CIMETIDINE; CYCLOSPORIN; DIGOXIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; FLUOXETINE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; LACIDIPINE; LERCANIDIPINE; LOSARTAN; METOPROLOL; MIDAZOLAM; NIFEDIPINE; SIMVASTATIN; WARFARIN;

ANKLE EDEMA; ASTHENIA; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE SEVERITY; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EMBASE; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MENTAL DISEASE; NERVOUSNESS; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VASODILATATION; VERTIGO;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIHYDROPYRIDINES; HUMANS; HYPERTENSION;

EID: 34047205050     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H299     Document Type: Review

References (40)

1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sortie P. The burden of adult hypertension in the United States, 1999-2000: a rising tide. Hypertension 2004;44:398-404.
2. MacMahon S, Rodgers A. The epidemiological association between blood pressure and stroke: implications for primary and secondary prevention. Hypertens Res 1994;17(suppl 1):S23-32.
3. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
4. Racial/ethnic disparities in prevalence, treatment, and control of hypertension-United States, 1999-2002. MMWR Morb Mortal Wkly Rep 2005;54:7-9.
5. Thorn T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151.
6. Freher M, Challapalli S, Pinto JV, Schwartz J, Bonow RO, Gheorgiade M. Current status of calcium channel blockers in patients with cardiovascular disease. Curr Prob Cardiol 1999;24:236-40.
7. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999-341:1447-57.
8. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-71.
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
10. Epstein M. Lercanidipine: a novel dihydropyridine calcium channel blocker. Heart Disease 2001;3:398-407.
11. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003;62:2449-72.
12. Forest Laboratories updates lercanidipine development. Forest Laboratories, Inc. Press Release. www.frx.com/news/PressRelease.aspx?ID= 639115 (accessed 2006 Mar 9).
13. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: short plasma half-life, long duration of action. J Cardiovasc Pharmacol 1997;29(suppl 1):S19-24.
14. Leonardi A, Poggesi E, Taddei C, et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997;29(suppl 1):S10-8.
15. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5, and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998;16:1831-88.
16. Guarneri L, Sironi G, Angelico P, et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997;29(suppl 1):S25-32.
17. Package insert (online). Vasodip (lercanidipine hydrochloride). Hadera, Israel: Dexcel Ltd./Dexxon Ltd. www.emed.co.il/emed/drugdb/DrugData/ Drugs/showdocleaf.asp?drug_id=4806 (accessed 2006 May 30).
18. Barchielli M, Dolfini E, Farina P, Leoni B, Vinaccia V, Tajana A. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol 1997; 29(suppl 2):S1-15.
19. Cafiero M, Giasi M. Long-term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997;29(suppl 2):S45-9.
20. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997;29(suppl 2):S31-5
21. Romito R, Pansini MI, Perticone F, Antonelli G, Pitzalis M, Rizzon P. Comparative effect of lercanidipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) study. J Clin Hypertens 2003;5:249-53.
22. De Giorgio LA, Orlandini F, Malasoma P, Zappa A. Double-blind cross-over study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999;60:511-20.
23. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-40.
24. Cherubini A, Fabris F, Ferrari E, Cucinotta D, Antonelli Incalzi R, Senin U. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003;37:203-12.
25. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovasc Pharmacol 1997;29(suppl 2):S26-30.
26. Barbagallo Sangiorgi GB, Putignano E, Calcara L, Barbagallo M. Efficacy and tolerability of lercanidipine vs captopril in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovasc Pharmacol 1997;29(suppl 2):S36-8.
27. James IGV, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002;16:605-10.
28. Barrios V, Navarro A, Esteras A, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Pressure 2002;11:95-100.
29. Paterna S, Licata S, Arnone C, Cottone C, Corrao S, Licata G. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997;29(suppl 2):S50-3.
30. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24:185-92.
31. Millar-Craig M, Shaffu B, Greenough A, Mitchell A, Mcdonald C. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens 2003;17:799-806.
32. Micheli D, Ratti E, Toson G, et al. Pharmacology of lacidipine, a vascular-selective calcium antagonist. J Cardiovasc Pharmacol 1991;17(suppl 4):S1-8.
33. Perelman M. Selection of initial and maintenance dosages for lacidipine, a new once-daily calcium antagonist for the treatment of hypertension. J Cardiovasc Pharmacol 1991;17(suppl 4):S14-9.
34. Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005;1:73-80.
35. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonists (either nifedipine or amlodipine) versus high-dose calcium antagonists monotherapy for systemic hypertension. Am J Cardiol 2000;86:1182-7.
36. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity, the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
37. Package insert. Norvasc (amlodipine besylate). New York, NY: Pfizer, September 2005.
38. Package insert. Plendil (felodipine). Wilmington, DE: AstraZeneca LP, November 2003.
39. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Improved tolerability of the dihydropyridine calcium channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl 2003;12:14-21.
40. Miller S, Parker A, Peterson C, et al. Express scripts drug trend report 2005-therapy class review. www.expressscripts.com/ourcompany/news/ industryreports/drugtrendreport/2005/ (accessed 2007 Feb 28).